Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | CASR | P41180 | 2/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6252974 | 0.90 | LOXL2 (0.51) | LOXL2MTNR1AMTNR1BHRH3CHRNA7 | |
| SCHEMBL13064053 | 0.87 | LOXL2 (0.49) | LOXL2MTNR1AMTNR1BHRH3CHRNA7 | |
| SCHEMBL7169246 | 0.82 | LOXL2 (0.69) | LOXL2MTNR1AMTNR1BHRH3CHRNA7 | |
| SCHEMBL31059889 | 0.82 | LOXL2 (0.69) | LOXL2MTNR1AMTNR1BHRH3CHRNA7 | |
| SCHEMBL12809346 | 0.82 | LOXL2 (0.47) | LOXL2MTNR1AMTNR1BHRH3CHRNA7 | |
| SCHEMBL14158511 | 0.82 | LOXL2 (0.56) | LOXL2MTNR1AMTNR1BHRH3CHRNA7 | |
| SCHEMBL1724157 | 0.82 | LOXL2 (0.59) | LOXL2MTNR1AMTNR1BHRH3CHRNA7 | |
| SCHEMBL9027554 | 0.81 | LOXL2 (0.58) | LOXL2MTNR1AMTNR1BHRH3CASR | |
| SCHEMBL28483740 | 0.81 | LOXL2 (0.53) | LOXL2MTNR1AMTNR1BHRH3CHRNA7 | |
| SCHEMBL28335219 | 0.81 | LOXL2 (0.67) | LOXL2MTNR1AMTNR1BHRH3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434695-B2 | Nitrogenous heterocyclic derivatives and their application in drugs | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2016-09-06 | — | — | US | disclosed |
| US-20150087639-A1 | Nitrogenous Heterocyclic Derivatives And Their Application In Drugs | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-03-26 | — | — | US | disclosed |
| US-8673904-B2 | Epoxide inhibitors of cysteine proteases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673904-B2 | Epoxide inhibitors of cysteine proteases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-03-18 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080176841-A1 | EPOXIDE INHIBITORS OF CYSTEINE PROTEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080176841-A1 | EPOXIDE INHIBITORS OF CYSTEINE PROTEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-07-24 | — | — | US | disclosed |
| EP-0959881-B1 | SYNTHETIC METHODS FOR THE PREPARATION OF INDOLYLQUINONES AND MONO- AND BIS-INDOLYLQUINONES PREPARED THEREFROM | SUGEN INC (US) | 2005-09-21 | — | — | EP | disclosed |
| CN-1535965-A | cyanine compound, filter and optical recording material | 旭电化工业株式会社 | 2004-10-13 | — | — | CN | disclosed |
| US-20040197705-A1 | Cyanide compound, optical filter, and optical recording material | ASAHI DENKA CO., LTD. (JP) | 2004-10-07 | — | — | US | disclosed |
| WO-2001021589-A2 | MONO- AND BIS-INDOLYLQUINONES AND PROPHYLACTIC AND THERAPEUTIC USES THEREOF | SUGEN, INC. (US) | 2001-03-29 | — | — | WO | disclosed |
| US-6110957-A | ANTITUMOR AGENT TREATING CELL PROLIFERATIVE DISORDERS SUCH AS CANCER, DYES, FUNGICIDES, BACTERICIDES | SUGEN, INC. (US) | 2000-08-29 | — | — | US | disclosed |
| US-6090838-A | USING 2,5-BISINDOL-3-YL-1,4-QUINONE | SUGEN, INC. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0959881-A1 | SYNTHETIC METHODS FOR THE PREPARATION OF INDOLYLQUINONES AND MONO- AND BIS-INDOLYLQUINONES PREPARED THEREFROM | Sugen, Inc. (US) | 1999-12-01 | — | — | EP | disclosed |
| CN-1192680-A | Methods and compositions for inhibiting adaptor protein/tyrosine kinase interactions | SUGEN INC (US) | 1998-09-09 | — | — | CN | disclosed |
| US-5786488-A | DEHYDROBROMINATION OF A DIBROMOBENZOQUINONES WITH AT LEAST ONE INDOLES IN A POLAR SOLVENT AND A METAL CARBONATE TO FORM AN ANTITUMOR AGENT | SUGEN, INC. (US) | 1998-07-28 | — | — | US | disclosed |
| US-5780496-A | Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions | SUGEN, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1998020874-A1 | SYNTHETIC METHODS FOR THE PREPARATION OF INDOLYLQUINONES AND MONO- AND BIS-INDOLYLQUINONES PREPARED THEREFROM | SUGEN, INC. (US) | 1998-05-22 | — | — | WO | disclosed |
| EP-0831809-A1 | METHOD AND COMPOSITIONS FOR INHIBITION OF ADAPTOR PROTEIN/TYROSINE KINASE INTERACTIONS | Sugen, Inc. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040115-A1 | METHOD AND COMPOSITIONS FOR INHIBITION OF ADAPTOR PROTEIN/TYROSINE KINASE INTERACTIONS | SUGEN, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087639-A1 | Nitrogenous Heterocyclic Derivatives And Their Application In Drugs | TNNC1, TNNI3, IAPP | LOXL2 2243/4885MTNR1A 1800/4885MTNR1B 2739/4885 |
| US-20040197705-A1 | Cyanide compound, optical filter, and optical recording material | HCN4, HCN2, HCN1 | LOXL2 1709/4885MTNR1A 1633/4885MTNR1B 1830/4885 |
| US-20080176841-A1 | EPOXIDE INHIBITORS OF CYSTEINE PROTEASES | SERPINB1, EPHX1, EPX | LOXL2 300/4885MTNR1A 3616/4885MTNR1B 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.